Don’t miss the latest developments in business and finance.

Alkem Laboratories launches anti-epileptic drug - Brivasure

Image
Capital Market
Last Updated : Mar 15 2021 | 2:50 PM IST
Alkem Laboratories has launched Brivasure, an affordable anti-epileptic drug for the treatment of Epilepsy in India.

Brivasure, Alkem's anti-epileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg - Rs.79.50/strip, Brivasure 50mg - Rs. 148.50/strip, Brivasure 75mg - Rs. 230/strip, Brivasure 100mg - Rs. 295/strip, post patent expiry of innovator product, of Brivaracetam as on 21 February 2021.

The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial onset seizure with or without secondary generalization. The drug has exhibited faster onset of action, efficacy with favorable safety profile.

Powered by Capital Market - Live News

Also Read

First Published: Mar 15 2021 | 2:32 PM IST

Next Story